0102030405
Bivalirudin: A Reversible Thrombin Inhibitor for Effective Anticoagulation
Detailed Description
Bivalirudin is a synthetic 20-residue peptide that acts as a reversible inhibitor of thrombin, a key enzyme involved in blood clot formation. By binding to the active site of thrombin, bivalirudin prevents the conversion of fibrinogen to fibrin, a crucial step in thrombus formation. Administered intravenously, bivalirudin plays a significant role in anticoagulation therapy. However, careful monitoring of hematocrit, activated partial thromboplastin time (aPTT), international normalized ratio (INR), and blood pressure is necessary due to its potential to cause blood stagnation.
Bivalirudin exhibits an inhibitory effect on both soluble and thrombus-bound thrombin in vitro. Importantly, this inhibitory effect remains unaffected by platelet-released products. With a dose-dependent manner, bivalirudin can extend plasma aPTT, thrombin time, and prothrombin time in normal human subjects. These characteristics make it particularly suitable for use in percutaneous coronary intervention (PCI) for patients with unstable angina.
Cardioembolic stroke, also known as cardiac stroke, occurs when emboli originating from the heart and aortic arch travel through the bloodstream, leading to cerebral arterial embolism and subsequent cerebral dysfunction. Cardiac strokes, compared to ischemic strokes of other etiologies, tend to be more complex in terms of underlying causes, more severe in terms of presentation, have a poorer prognosis, and a higher recurrence rate. Approximately 70% of all strokes with a cardiac origin are attributed to atrial fibrillation (AF). Anticoagulant therapy appropriate to the patient's condition is essential for the secondary prevention of AF-related cardioembolic stroke.
When considering the use of bivalirudin, it is crucial to keep in mind the monitoring requirements for optimal patient safety. Changes in hematocrit, aPTT, INR, and blood pressure should be closely observed to detect any potential complications associated with blood stagnation. Regular monitoring allows healthcare professionals to adjust the dosage and ensure that the patient is receiving the appropriate level of anticoagulation.
Bivalirudin, as a reversible thrombin inhibitor, plays a vital role in anticoagulation therapy. By inhibiting thrombin, it prevents the formation of fibrin and subsequent clot formation. This makes it an effective option for use in percutaneous coronary intervention, particularly for patients with unstable angina.
If you have any related needs for Bivalirudin, please do not hesitate to contact us for a better price.
If you have any related needs for Bivalirudin, please do not hesitate to contact us for a better price.
Specification
